Protective effects of Puriton® on acute pancreatitis
Rattachement africain : kr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Objectives: Puriton® is the electrolyte enriched water consisting of 31 essential minerals from biotite, kaolinite, montmorillonite, serpentine, and clinochlore, and vermiculite. It has been reported to be bactericidal and virucidal. However, the protective effect of Puriton® against acute pancreatitis (AP) has not yet been studied. Therefore, we aimed to evaluate the protective effect of Puriton® against cerulein-induced AP.Methods: AP was induced by intraperitoneal injections of cerulein (50 μg/kg) hourly for 6 times. Puriton® (100, 300, 500, or 700 μL) was administered orally 1 hour before the first cerulein injection. Mice were sacrificed 6 hours after the last cerulein injection. Pancreas, lung, and serum samples were quickly collected for further analysis.Results: Administration of Puriton® did not reduce the ratio of pancreas weight to body weight. However, the increased serum amylase and lipase were decreased in the Puriton® administration group, and histological damage to pancreas and lung tissue was suppressed in the Puriton® 100 and 300 μL administration groups, but not in the Puriton® 500 and 700 μL administration groups. Additionally, among pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, the mRNA level of only IL-6 was decreased by Puriton® administration.Conclusion: In summary, we showed that the administration of Puriton® improved the severity of cerulein-induced AP, suggesting the possibility of being an effective drug for AP.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Protective effects of Puriton® on acute pancreatitis
- Date Crossref
- 01/09/2024
- Éditeur
- The Society of Korean Medicine
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Wonkwang University Hanbang Cardio-Renal Syndrome Research Center pays non établi dans la noticeUniversité ou école supérieure
-
College of Korean Medicine Department of Pharmacology pays non établi dans la noticeUniversité ou école supérieure
-
Inc. Kadesh pays non établi dans la noticeEntreprise
-
College of Pharmacy Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
Hanbang Cardio-Renal Syndrome Research Center — Wonkwang University, Department of Pharmacology — College of Korean Medicine et Kadesh — Inc., avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.